<DOC>
	<DOCNO>NCT00216697</DOCNO>
	<brief_summary>One purpose study evaluate effectiveness safety long term treatment patient complete precede phase I/II study . The purpose evaluate effectiveness safety patient re-treated drug recommend dose .</brief_summary>
	<brief_title>An Extension Study Provide Bortezomib Patients With Relapsed Refractory Multiple Myeloma Who Previously Participated Bortezomib Phase I/II Study Who May Benefit From Re-Treatment With Continuation Bortezomib Therapy</brief_title>
	<detailed_description>Multiple myeloma kind malignant disease organ produce blood cell bone marrow . It poor prognosis , especially patient relapse repeatedly . Effective treatment strongly expect relapsed patient Japan . This open label multiple center study evaluate effectiveness safety bortezomib . This study extension re-treatment study patient administer bortezomib precede Phase I/II study . For extension treatment , dose previous study administer vein bolus twice weekly follow 10-day rest ( 3-week cycle ) . For re-treatment , recommend dose determined Phase I/II study administer 3-week cycle .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Complete 6 cycle treatment precede phase I/II study response ( CR , PR , MR NC ) obtain 6 cycle treatment precede phase I/II study investigator considers patient expect benefit antitumor effect , pain relief improvement performance state Patients Grade &gt; =3 nonhematologic toxicity Grade 4 hematologic toxicity precede phase I/II study extension treatment study Investigator consider patient expect benefit drug antitumor effect , pain relief improvement performance state . Patient known HBs antigen positive , HCV antibody positive HIV antibody positive ( check require patient receive blood product phase I/II study ) Patients receive GCSF product blood transfusion within 7 day start treatment Disease progress observe phase I/II study patient receive recommend dose Patients suffer Grade &gt; =2 peripheral neuropathy Grade &gt; =2 neuropathic pain Patient New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , acute ischemia active conduction system abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Ubiquitin</keyword>
	<keyword>Boronic acid</keyword>
	<keyword>Bortezomib</keyword>
</DOC>